The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

Elahere shows a 37% lower risk of tumor progression or death vs. chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

Genmab acquired the biotech for $1.8 billion last year, securing rights to a challenger to AbbVie’s Elahere. AbbVie alleges that ProfoundBio initially failed to produce a viable ADC pipeline and ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found great dividend stocks to own for the long term that pay you to wait for better ...

These deals added major growth drivers to the company's lineup, including cancer drug Elahere, cosmetic therapy Botox, and antipsychotic Vraylar. In addition, AbbVie's pipeline appears to be ...